121 related articles for article (PubMed ID: 11504826)
1. Kinetics of P-glycoprotein-mediated efflux of paclitaxel.
Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2001 Sep; 298(3):1236-42. PubMed ID: 11504826
[TBL] [Abstract][Full Text] [Related]
2. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
Lin JT; Sharma R; Grady JJ; Awasthi S
Drug Metab Dispos; 2001 Feb; 29(2):103-10. PubMed ID: 11159798
[TBL] [Abstract][Full Text] [Related]
3. Computational model of intracellular pharmacokinetics of paclitaxel.
Kuh HJ; Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2000 Jun; 293(3):761-70. PubMed ID: 10869374
[TBL] [Abstract][Full Text] [Related]
4. Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling.
Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2003 Feb; 304(2):773-80. PubMed ID: 12538833
[TBL] [Abstract][Full Text] [Related]
5. Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein.
Li D; Au JL
Pharm Res; 2001 Jul; 18(7):907-13. PubMed ID: 11496948
[TBL] [Abstract][Full Text] [Related]
6. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
7. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Gallo JM; Li S; Guo P; Reed K; Ma J
Cancer Res; 2003 Aug; 63(16):5114-7. PubMed ID: 12941842
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
9. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Barthomeuf C; Demeule M; Grassi J; Saidkhodjaev A; Beliveau R
Planta Med; 2006 Jun; 72(7):634-9. PubMed ID: 16739070
[TBL] [Abstract][Full Text] [Related]
10. Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?
Declèves X; Niel E; Debray M; Scherrmann JM
Toxicol Appl Pharmacol; 2006 Dec; 217(2):153-60. PubMed ID: 16978677
[TBL] [Abstract][Full Text] [Related]
11. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
Xiao JJ; Foraker AB; Swaan PW; Liu S; Huang Y; Dai Z; Chen J; Sadée W; Byrd J; Marcucci G; Chan KK
J Pharmacol Exp Ther; 2005 Apr; 313(1):268-76. PubMed ID: 15634944
[TBL] [Abstract][Full Text] [Related]
12. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
13. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells.
Hamilton KO; Topp E; Makagiansar I; Siahaan T; Yazdanian M; Audus KL
J Pharmacol Exp Ther; 2001 Sep; 298(3):1199-205. PubMed ID: 11504821
[TBL] [Abstract][Full Text] [Related]
15. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates.
Kurdziel KA; Kiesewetter DO; Carson RE; Eckelman WC; Herscovitch P
J Nucl Med; 2003 Aug; 44(8):1330-9. PubMed ID: 12902425
[TBL] [Abstract][Full Text] [Related]
17. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
18. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
19. Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure.
Wan CP; Jackson JK; Pirmoradi FN; Chiao M; Burt HM
Ultrasound Med Biol; 2012 May; 38(5):736-44. PubMed ID: 22425383
[TBL] [Abstract][Full Text] [Related]
20. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
